Sort   by:  
 Page size 
UnknownTherapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Not available
S-EPMC8362592 | biostudies-literature
UnknownInterleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses.
Not available
S-EPMC11560592 | biostudies-literature
UnknownSmall-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.
Not available
S-EPMC10711013 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594 | biostudies-literature
UnknownMethylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Not available
S-EPMC6162272 | biostudies-literature
UnknownTiming of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer.
Not available
S-EPMC11258338 | biostudies-literature
UnknownPaclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.
Not available
S-EPMC4015028 | biostudies-literature
UnknownValidating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
Not available
S-EPMC2634713 | biostudies-literature
UnknownBreast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study.
Not available
S-EPMC3220608 | biostudies-literature
UnknownHigh levels of genomic aberrations in serous ovarian cancers are associated with better survival.
Not available
S-EPMC3553118 | biostudies-literature
Sort   by:  
 Page size